Susan Daneman
Research Subjects
Research Interests
Susan Daneman has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Bao N Puente
Department of Pediatrics, UTSW Medical Center, Dallas, Texas 75235, USA
1 shared publication - Bibhuti Bhusan Das
Methodist Children’s Hospital
1 shared publication - Jodi Mcdermott
Children’s Health Heart Institute, Dallas, Texas 75235, USA
1 shared publication - Kristin Anton
Children’s Health Heart Institute, Dallas, Texas 75235, USA
1 shared publication - Leah Knox
Children’s Health Heart Institute, Dallas, Texas 75235, USA
1 shared publication - Nelia Soares
Children’s Health Heart Institute, Dallas, Texas 75235, USA
1 shared publication
Latest Publications
- Open Access
- 8 April 2018
- Published by MDPI AG in Medical Sciences
- Vol. 6 (2) , 30
Cimetidine: A Safe Treatment Option for Cutaneous Warts in Pediatric Heart Transplant Recipients
Background and Objectives: Immunosuppressed individuals are at particularly increased risk for human papilloma virus-related infections. The primary objective of our study is to determine if there are any adverse effects associated with high-dose cimetidine treatment. A secondary objective is to report our experience with cimetidine in the treatment of cutaneous warts in pediatric heart transplant recipients. Methods and Results: This was a retrospective observational study. A total of 8 pediatric heart transplant recipients diagnosed with multiple recalcitrant warts were the subject of the study. All patients were treated with cimetidine (30–40 mg/kg/day) in two divided doses for 3 to 6 month durations. All patients had complete resolution of their lesions except 1 patient who had no clinical improvement. Of these 8 patients, one had recurrence of warts at one year follow-up, which resolved with restarting cimetidine therapy. One patient who had only 3 months of cimetidine therapy had immediate relapse after cimetidine was stopped. None of them had significant change in their tacrolimus trough, serum creatinine, and alanine transaminase levels. No adverse events were reported except one patient experienced mild gynecomastia. Conclusion: Cimetidine can be a safe and alternative treatment option for multiple warts in pediatric heart transplant recipients.
- 8 April 2018
- Published by MDPI AG in Medical Sciences
- Vol. 6 (2) , 30
Open AccessCimetidine: A Safe Treatment Option for Cutaneous Warts in Pediatric Heart Transplant Recipients
Background and Objectives: Immunosuppressed individuals are at particularly increased risk for human papilloma virus-related infections. The primary objective of our study is to determine if there are any adverse effects associated with high-dose cimetidine treatment. A secondary objective is to report our experience with cimetidine in the treatment of cutaneous warts in pediatric heart transplant recipients. Methods and Results: This was a retrospective observational study. A total of 8 pediatric heart transplant recipients diagnosed with multiple recalcitrant warts were the subject of the study. All patients were treated with cimetidine (30–40 mg/kg/day) in two divided doses for 3 to 6 month durations. All patients had complete resolution of their lesions except 1 patient who had no clinical improvement. Of these 8 patients, one had recurrence of warts at one year follow-up, which resolved with restarting cimetidine therapy. One patient who had only 3 months of cimetidine therapy had immediate relapse after cimetidine was stopped. None of them had significant change in their tacrolimus trough, serum creatinine, and alanine transaminase levels. No adverse events were reported except one patient experienced mild gynecomastia. Conclusion: Cimetidine can be a safe and alternative treatment option for multiple warts in pediatric heart transplant recipients.